CDK4-dependent phosphorylation of USP35 promotes the growth of ER+ breast cancer through the mTOR-SOX2 axis
The majority of estrogen receptor-positive (ER + ) breast cancers are treated with endocrine therapy plus CDK4/6 or mTOR inhibitors, but resistance persists. Deubiquitinase USP35 overexpression promotes tumor growth, yet its regulation by post-translational modifications remains unknown. We showed that CDK4 phosphorylated USP35 at Ser982, which was critical for ER+ breast cancer cell growth in vitro and in vivo. Mechanistically, USP35 interacted with TSC2, Ser982 contributed to USP35-mediated reduction of TSC2 protein and its association with TSC1, thereby activating mTOR signaling. Elevated signaling upregulated SOX2, driving oncogenic effects. Importantly, the CDK4/6 or mTOR inhibitor effectively suppressed the growth of USP35-high ER+ breast cancer cells and tumors. Furthermore, the phospho-USP35 Ser982 was positively correlated with the phospho-4E-BP1 level in ER+ breast cancer tissues. Our findings uncover that CDK4/USP35/mTOR/SOX2 signaling axis promotes ER+ breast cancer progression. ER+ breast cancer with high phospho-USP35 S982 level might benefit from CDK4/6 or mTOR inhibitor-based therapies.
Authors
- Haihua Gu (ORCID: https://orcid.org/0000-0003-2154-9900)
- Rixu Lin (ORCID: https://orcid.org/0000-0003-2498-8116)
- Jiawei Cao (ORCID: https://orcid.org/0000-0001-6268-5912)
- 陈佳园
- Shuifeng Liang
- Ju Huang
- Jiayi Shao
- Dejin Shi
- Guang Wu
- Jiayu Chen
- Tao Wu
- Licai He
- Junfeng Lai
Institutions
- Wenzhou Medical University (CN)
- First Affiliated Hospital of Wenzhou Medical University (CN)
Publication Details
- Journal
- Communications Biology
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1038/s42003-026-11337-y
- Primary Topic
- PI3K/AKT/mTOR signaling in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00